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Practice points
• Secondary progressive multiple sclerosis (SPMS) is characterized by a progressive accumulation of disability after
an initial relapsing course. The diagnosis of SPMS is often established retrospectively owing to indistinct clinical
features of disease progression, unclear diagnostic guidance and lack of imaging and biomarkers to monitor the
transition.
• A holistic understanding of the current and future patient journey of SPMS across seven European countries was
undertaken to identify overarching unmet needs encountered by all key stakeholders involved in the
management of multiple sclerosis (MS).
• Elemental findings from the key stakeholders (nurses, neurologists, payers) who participated in this international
expert group meeting highlighted an uncertainty among healthcare professionals over SPMS disease definition
and its differentiation with relapsing-remitting MS, as well as a reluctance to diagnose due to the absence of
effective therapeutic options. The standard of therapeutic care for a patient with SPMS also exhibits diversity
across regions.
• Experts consider that inputs from physiotherapists, rehabilitation doctors, neuropsychologists and social workers
are also beneficial in the detection and diagnosis of SPMS primarily performed by specialized neurologists.
• With an enriched pathophysiological knowledge of SPMS disease and a distinct disease definition in future, SPMS
may not remain as devastating for patients and different stakeholders.
• The role of the pharmaceutical industry is important in enhancing SPMS disease awareness among patients and
all stakeholders involved in the SPMS patient journey.
• The emergence of digital tools and robust real-world evidence will aid drug developers in the rapid advancement
of novel therapeutics for SPMS.
• Prompt clinical evidence on the efficacy of novel treatments will also rapidly expand the SPMS treatment
armamentarium. However, a strengthened treatment paradigm will require guidelines for the reassessment of
treatment options. Combined with enhanced patient monitoring and consolidated caregivers support, the quality
of life of patients with SPMS can be transformed.
The transition from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis
(SPMS) remains a clinical challenge owing to the heterogeneous course of the disease, indistinct disease
progression and lack of availability of validated biomarkers and diagnostic tools. This article summarizes
the outcomes from an international expert group meeting conducted to validate the preliminary research
findings gathered through interviews with primary healthcare stakeholders and pharmaceutical represen-
tatives, and to understand the current and future patient journey of SPMS across seven European coun-
tries. We highlight the uncertainty in SPMS diagnosis and management and, consequently, the need for
uniform assessment guidelines, enhanced awareness and a collaborative effort between the stakeholders
associated with SPMS patient care and the pharmaceutical industry.
Neurodegener. Dis. Manag. (Epub ahead of print) ISSN 1758-202410.2217/nmt-2020-0054 C© 2020 Øivind Torkildsen and all the co-authors
White Paper Torkildsen, Linker, Sesmero et al.
Lay abstract: This article summarizes the findings from an international expert group meeting conducted
to understand the current and future patient journey of secondary progressive multiple sclerosis (SPMS),
across seven European countries. Although there are a number of challenges in the diagnosis and treat-
ment of patients with SPMS, it is evident that the collaborative efforts of associated stakeholders (neurolo-
gists, nurses, caregivers, payers, patients and the pharmaceutical industry), along with proper knowledge
on diagnosis/treatment, and availability of real-world data in the future, will allow for optimal care that
will improve the quality of life of people living with SPMS.
Tweetable abstract: Uncertainty in SPMS diagnosis and management emphasizes the need for robust as-
sessment guidelines, enhanced awareness and collaborative efforts among stakeholders to allow optimal
care of SPMS patients
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Multiple sclerosis (MS), a neuroinflammatory disease characterized by demyelination and axonal loss [1], is usually
diagnosed at a young age (age: 20–40 years). MS prevalence rises with increase in latitude; it is the lowest in eastern
sub-Saharan Africa (3.3 cases per 100,000), central sub-Saharan African (2.8) and Oceania (2.0), and the highest
in North America (164.6), Western Europe (127) and Australasia (91.1). Additionally, there is a strong female
preponderance [2]. As of 2015, approximately 700,000 people in Europe were living with MS [3], and, after traffic
accidents, MS is the leading cause of disability in young adults globally [4]. MS manifests itself distinctively in
patients and significantly affects their quality of life, healthcare costs, work capacity and productivity [5,6].
Secondary progressive MS (SPMS) is characterized by a progressive accumulation of disability after an initial
relapsing course, with approximately 80% of patients initially diagnosed with relapsing-remitting MS (RRMS)
transitioning to SPMS within 20 years if not adequately treated [7,8]. The diagnosis of SPMS is often established
retrospectively owing to indistinct clinical features of disease progression, unclear diagnostic guidance in the 2017
revised McDonald criteria, and lack of imaging and biomarkers to monitor the transition [9–11]. SPMS is further
distinguished as either active (with relapses and/or evidence of new MRI activity) or nonactive, with progression
(accumulation of disability over time, independent of any relapse) and without progression [12] assessed generally
using the Expanded Disability Status Scale (EDSS) [9,13]. The recent explanation on classification criteria of MS
phenotypes emphasizes the inclusion of time frame, while defining the current disease state through assessment
of activity (evidenced by clinical relapses or imaging) and assessment of progression (clinical evidence of disability
worsening that is independent of relapses) over a given period of time in patients who are in a progressive phase
of the disease. In addition, the terms worsening and progressing, or disease progression, should be used more
accurately when describing the MS disease course [11]. The recommended time frame for evaluating active disease
or a progressing disease is at least once in a year.
Periodic monitoring of disease activity and progression, as well as availability of potential disease-modifying
therapies (DMTs), govern treatment decisions [12,14,15]. Hence, a holistic understanding of the SPMS patient journey
is critical to identify overarching unmet needs encountered by all key stakeholders involved in the management
of MS. This paper is based on a meeting of MS experts held in December 2019 and highlights unmet needs and
country-specific idiosyncrasies in order to identify key priority areas to improve the MS ecosystem across Europe.
Methods
The detailed step-by-step methodology followed for this study is described below.
Primary & secondary research
Primary and secondary research was conducted across seven European countries (France [FR], Germany [DE],
Italy [IT], Spain [SP], the UK, Switzerland [CH] and Norway [NOR]) to gather a preliminary understanding
of the unmet needs and future expectations across different stakeholders. Primary research comprised in-depth
qualitative interviews with 58 randomly selected local experts encompassing the main stakeholders involved in the
management of SPMS (specialized neurologists, MS nurses and payers) (Figure 1).
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Figure 1. Respondent profiles of stakeholders from different countries.
CEESP: Commission Évaluation Économique et de Santé Publique (Committee for Economic and Public Healthcare
Evaluation); CEPS: Comité Economique des Produits de Santé (Economic Committee of Healthcare Products); CHG:
Centre Hospitalier Générale (general or local hospital); CHU: Centre Hospitalier Universitaire (university
hospital); CoE: Centers of excellence; CT: Commission de la Transparence (Transparency Committee); MS: Multiple
sclerosis; SH: Social health; SHI: Social health insurance.
International expert group meeting
Validated findings from the primary research were used to identify key topics and develop a discussion guide for
the faculty of experts invited to the international expert group meeting. The meeting was organized into three
workshops: healthcare professionals (HCPs) – six international MS clinical experts from SP, DE, CH, FR, UK
and NOR; payers – six experts in access and price negotiation from SP, UK, FR, DE and NOR; and nurses
– four MS nurses from centers of excellence in the UK, DE, FR and IT. Early interviews during the primary
research revealed that the patient journey could be divided into five steps – prediagnosis, diagnosis, work-up and
treatment decision, monitoring and re-assessment, and this was adapted for subsequent interviews. Different aspects
were discussed separately with neurologists and nurses, including current and future expectations regarding SPMS
disease awareness and epidemiology, patient identification, diagnosis, disease management, treatment decisions and
monitoring, and the role of treatment cost, as well as the role of multi-stakeholders in the patient journey. The
payers’ discussion was focused on disease awareness and epidemiology, current treatment options and unmet needs,
disease and economic burden, access level and restrictions, current and future value drivers, and future pricing and
reimbursement drivers in MS.
Consensus
The outcome of the expert group meeting validated the preliminary understanding of the unmet needs and future
expectations across different stakeholders. An alignment and consensus around the main topics characterizing the
current SPMS patient journey is presented in the following sections.
Results
Current patient journey through SPMS
SPMS disease awareness: perception versus reality
An integral part of the SPMS patient journey is to identify the disease transition from RRMS to SPMS. With the
definition of clinical MS courses in 1996, the latest revision in 2020 emphasized the importance of a time-based
assessment of the current disease status of an MS patient. However, an ambiguity around the disease definition
was seen among neurologists, payers and nurses across the participating European countries [9,11]. SPMS is largely
perceived as a continuum of RRMS, and an increasing tendency exists among clinicians to diagnose the disease
based on the cessation of inflammatory activity (relapses or MRI activity), rather than the recognition of progressive
clinical disability independent of relapses (even when they are still occurring), as described by the 2013 consensus
criteria [9,11].
Primary and secondary research shows that neurologists confined to a limited number of MS centers have a robust
understanding of SPMS diagnosis. However, the less specialized HCPs and nurses may have suboptimal knowledge
regarding the SPMS diagnosis and its clinical course. In addition, it is noteworthy that the clinicians exhibit a
reluctance to confirm the SPMS diagnosis owing to the lack of effective treatment. Experts in MS management
consider symptomatic cognitive decline/depression/fatigue, along with MRI findings, and EDSS assessment, vital
for the assessment of SPMS. However, there is a time lag in worsening of symptoms and evaluation of disease activity
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Limited confidence in managing patients among HCPs
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Figure 2. Perspectives of multiple sclerosis specialists and payers toward perception of secondary progressive
multiple sclerosis population.
HCP: Healthcare professional; MS: Multiple sclerosis; RRMS: Relapsing-remitting MS; SPMS: Secondary progressive MS.
with MRI [16]. The prolonged patient journey and symptomatic variability also make it challenging to distinguish
the point of transition from RRMS to SPMS. In this regard, nurses play a significant role in determining the first
signs of disease progression and relaying the information to the neurologists. Community nurses have better clarity
on the patient’s symptomatic transition as they dedicate more time to and closely monitor their patients [17,18].
Therefore, although the diagnosis of SPMS is primarily a neurologist’s role, the responsibility of the nurses in
providing insights on symptomatic self-reporting cannot be undermined.
Across the seven countries, approximately 20–30% of the currently DMT-standard of care-treated MS patients
are diagnosed with SPMS. The uncertainty in disease definition across clinicians, insufficient MS-specialized
neurologists, delayed diagnosis, drug label constraints and unavailability of effective treatment options suggest
under-reporting of the SPMS disease burden. Moreover, payers rely on real-world evidence (RWE) studies to
estimate MS prevalence, which can be a concern since the data from controlled settings may not truly represent the
real-world burden. Figure 2 summarizes the perspectives of MS specialists and payers toward perception of SPMS
population by country.
SPMS: symptoms to diagnosis
In the UK and Germany, nurses are frequently the first to recognize and record the symptomatic changes that
support the diagnosis of SPMS. Furthermore, in the UK, nurses involved in the initial patient assessment are mostly
involved in diagnosis.
In Italy, SPMS diagnosis relies exclusively on the patient’s response, due to the absence of an objective tool for
quantification of progression. Because of the slow progression of SPMS, disease worsening is nonapparent in terms
of EDSS scores during the initial progressive phase. To confirm an SPMS diagnosis, patients’ clinical symptoms are
first reviewed, followed by evaluation of disease activity through MRI.
In the UK, the National Institute for Health and Care Excellence (NICE) guidelines recommend at least one
annual MS consultation and therefore, it is difficult to see a patient every 3–6 months to confirm disease worsening.
Occasionally, it may take up to 3–4 years to determine the progression as the interval between doctor visits and
MRI is approximately a year. Most patients initially experience a denial phase toward the SPMS diagnosis owing
to the unavailability of effective treatment options and potential loss of motor function.
Apart from specialized neurologists, physiotherapists in Germany and the UK, rehabilitation specialists and
social workers in France and the UK, and neuropsychologists in Italy, are usually involved in the detection and
diagnosis of SPMS. In Germany and the UK, detection of disease progression depends on the size and dynamic of
the center. The role of the caregiver is also important in comprehending the signs of progression, although currently
it is overlooked (Figure 3).
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Figure 3. Secondary progressive multiple sclerosis patient’s ECOSYSTEM.
GP: General practitioner; HCP: Healthcare professional; MS: Multiple sclerosis; PAG: Patient advocacy group;
PharmaCo: Pharmaceutical company; RR: Relapsing-remitting; SP: Secondary progressive; Spec: Specialist; SPMS:
Secondary progressive MS; Tx: Treatment.
Management of SPMS
There was a general agreement that the current treatment goal for SPMS is to halt disease progression (defined
as no change in the EDSS score) and prevent worsening of symptoms. The management of SPMS includes:
pharmacological management of the disease, in other words, drugs with a relapsing indication or symptomatic drugs;
and nonpharmacological management, in other words, rehabilitation and physiotherapy to manage symptoms such
as fatigue, brain fog and spasticity [19].
Although several DMTs are approved for the relapsing form of the disease, very few DMTs are specifically
approved for SPMS [20]. Cladribine received European Commission (EC) approval in 2017 for relapsing MS (RMS
and active SPMS) [21]. Siponimod, a selective modulator of sphingosine-1-phosphate receptor, was also approved
by the EC in 2020 for the management of active SPMS [22]. Mitoxantrone is approved by the US FDA and
recommended as per the American Academy of Neurology and European Committee for Treatment and Research
in Multiple Sclerosis guidelines for the treatment of SPMS [15,23]. In some cases, neurologists view ocrelizumab (and
other high-efficacy therapies) as an alternative to treat RMS patients, as it can be prescribed without confirmation
of SPMS diagnosis and patients can be switched back to other RRMS treatments if they do not respond to
ocrelizumab.
Multiple barriers exist in the management of patients with SPMS. A huge knowledge gap concerning SPMS and
its management exists among general neurologists. In all countries, neurologists are reluctant to switch treatment
during transition, mainly owing to the lack of safe and cost-effective treatment options. Recent therapeutic agents
faced challenges in reimbursements, which in turn increased the off-label use of MS drugs. The key barriers
to treatment reimbursement vary from country to country. In Germany, lack of information on recommended
treatments in health insurance and no acceptance of indirect comparisons by the Federal Joint Committee (GBA –
Gemeinsamer Bundesausschuss) are the key deterrents to SPMS treatment reimbursement. In France, unavailability
of robust epidemiology data to justify volume estimations acts as a barrier to treatment reimbursement. In Italy
and Spain, RWE may be useful in optimizing drug positioning, and in facilitating patients’ treatment access and
outcomes. With regard to budget impact analysis and cost–effectiveness, payers from all countries primarily focus
on direct medical and nonmedical costs. The indirect medical costs play a secondary role in cost–effectiveness
analysis, and societal costs do not impact price and reimbursement decisions. The heterogeneity in the active
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Figure 4. Different stakeholders involved and their role in the management of secondary progressive multiple
sclerosis patients.
GP: General practitioner; HCP: Healthcare professional; MS: Multiple sclerosis; RR: Relapsing-remitting; SPMS:
Secondary progressive MS; Tx: Treatment.
SPMS population that includes rapidly progressive and older patients who are without treatment access, hinders
the cost/benefit evaluation of a therapeutic agent.
Monitoring & reassessment
Owing to the long patient journey, continuous monitoring to check disease progression is vital in MS, and nurses
play a primary role in this regard. A higher monitoring frequency for patients with RRMS, which usually varies
from 3 months to a year, could help identify new SPMS cases. While neurologists play a key role in diagnostic and
treatment decisions, nurses and other HCPs are important for prediagnosis and monitoring (Figure 4). Moreover,
the role of nurses is not so much focused on the detection of progression signs and diagnosis of SPMS, but rather
on monitoring. In the UK, nurses can provide critical information to the MS physicians, which may be relevant
during the diagnosis. In Germany, nurses are usually involved in monitoring patients every 3–6 months, which
may help in detecting transition to SPMS. In all seven countries, monitoring depended on the size and dynamics of
the MS center. The patient’s caregiver and family also play a pertinent role in monitoring, in terms of support and
assessment of the symptoms of disease progression. Neurologists are largely involved in the treatment, monitoring
and periodical reassessment of patients with SPMS. In Spain, Italy and France, most patients are managed at MS
centers of excellence. In the UK, in addition to neurologists, general practitioners with expertise in neurology play
an important role in patient management; while in Germany, monitoring and reassessment is done by neurologists
at MS centers, as well as office-based neurologists. However, the responsibilities of the multidisciplinary teams and
rehabilitation specialists in monitoring patients with SPMS are currently limited.
According to the panel discussion, nearly 10–30% of patients with SPMS (UK and Norway: 10–20%; France:
∼30%; Italy, Switzerland and Spain: <10%; Germany: ∼20%) are lost in the system after SPMS detection owing
to apprehension regarding the lack of effective treatment, long waiting times for MRI and mobility issues. However,
once patients start receiving their SPMS treatment, adherence is not a grave concern unless there are cognitive or
emotional issues, ineffective treatment or any adverse effects. As per the experts’ opinion, only 5–10% of patients
with SPMS reportedly display nonadherence to treatment.
Future patient journey
Expectations from neurologists
The primary objective for neurologists should be early diagnosis of SPMS and timely initiation of appropriate
treatment, with no anticipation of major disruptive events impacting diagnosis. However, this remains aspirational
considering the time it takes to confirm SPMS.
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Expectations from MS nurses
Nurses play an active role in the recognition of disease transition and often discuss this with their patients.
Consistent communication with patients and increased awareness of the disease among nurses may facilitate an
earlier diagnosis. Patient-reported outcomes (PROs) are essential in the identification of the right signs of disease
progression [24]. In the UK, although the focus is on RRMS, an increased awareness of SPMS is imperative for early
diagnosis.
More DMT options necessitate safety monitoring of new drugs, progression monitoring and patient education
on the expanded drug access. During the treatment phase, a greater workforce, digital tools and setting the right
expectations on the effectiveness of emerging therapies among patients, neurologists and caregivers could galvanize
SPMS management [25].
Overall, change in the relapsing-remitting monitoring approach, greater attention to SPMS detection, and
increased contact and collaboration between nurses and physicians will potentially expedite SPMS reporting.
Digital applications to support remote patient tracking may aid in patient monitoring, and nurses would need to
be trained in using these platforms.
Expectations from payers
To shape a distinct SPMS landscape in the future, clarity on SPMS definition, epidemiological data and increased
awareness on SPMS is essential. Availability of data on indirect comparisons, RWE and subgroup of patients with
rapid progression will be useful in decision-making on disease budget allocations [26]. More adaptive trial designs
that can demonstrate satisfactory effect sizes in subgroups of patients with rapid progression are imperative.
Payers expect EDSS scores to remain as the gold standard for their evaluations. A composite end point that
measures both inflammation and disease progression could be useful for physicians, but not for payers as it will
not allow for comparisons with already existing products. Payers do foresee value in digital tools and applications,
although with a low impact on price and reimbursement. However, digital applications independent of patient
input are preferred as patients tend to get demotivated about feeding in their data after a few months of treatment.
Role of pharmaceutical industry
Although significant progress has been achieved in RRMS treatment, the same is yet to be replicated in SPMS
disease diagnosis and treatment. This lack of development can be explained by an insufficient understanding of
SPMS pathophysiology [27] and unclear diagnostic criteria [28]. The pharmaceutical industry is expected to provide
support for minimizing the ambiguity in SPMS disease definition [13] and improving patients’ disease awareness.
Pharmaceutical companies must remain highly involved in raising awareness and continue educational initiatives,
such as congresses, symposiums and workshops, training programs, patient networks and digital applications for
tracking patients’ evolution and detection of disease progression. Digital tools [29] can gather real-world data that
can encourage patient education and transcend barriers to disease awareness.
For SPMS research to be compelling and clinically impactful, collaborative efforts are needed between the
pharmaceutical industry and multi-stakeholders involved in SPMS patient care. There is a pressing need for
pharmaceutical companies and HCPs to support nurse education, particularly on the psychological impact of
SPMS on patients. Increased awareness in patients and caregivers on the disease and its treatments through
dedicated communities is also necessary. Furthermore, inclusion of PROs in the clinical trials will highlight the
real-added value of new treatments. Pharmaceutical resources for the training and education of HCPs must be
strengthened (Figure 5).
Discussion
A high level of heterogeneity exists in current clinical practice regarding the diagnosis and standard of care for
SPMS. In most countries, neurologists are the key prescription decision-makers, and payers have limited control
in this regard, except in complex SPMS cases for which neurologists may seek advice from multidisciplinary teams
while choosing the right treatment. Furthermore, regulating neurologists’ treatment decisions is challenging, given
the lack of clarity in differentiation between MS phenotypes and lack of head-to-head treatment comparisons in
clinical trials. Therefore, it is essential to address different aspects in the patient journey of SPMS.
Essentially, disease monitoring in an SPMS patient involves patient history, clinical examination and MRI
markers of disease progression when available. Patients’ feedback regarding the worsening of their condition and
side effects of the ongoing treatment is fundamental in understanding the efficacy of any therapy. Therefore, it
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Figure 5. Future patient journey with secondary progressive multiple sclerosis.
HCP: Healthcare professional; MS: Multiple sclerosis; RRMS: Relapsing-remitting MS; SPMS: Secondary progressive MS;
Tx: Treatment.
would be desirable to take into consideration more PROs together with MRI and other clinical outcomes, in
particular, the outcomes relevant for patients. Additionally, increased awareness of SPMS and advancements in
monitoring the approach of patients with RRMS may help detect SPMS earlier. In this regard, digitals tools are key,
as patients could monitor themselves and report outcomes. The universal implementation of digital tools, validated
with long-term cohort data and the opinions of allied multidisciplinary teams, remains vital for the monitoring
and reassessment of patients with SPMS [25].
Complete MS biosignature development will be crucial, which could lead to the use of serum levels of neu-
rofilament light chain, GFAP, along with the established MRI markers of disease progression to monitor disease
advancement instead of waiting for the clinical worsening [30,31]. It is also essential for clinicians managing patients
with SPMS to improve collaboration and referral pathways as patients display multiple symptoms and potential or-
gan toxicities due to DMTs. The recent emergence of oral medications, an easier mode of administration specifically
approved for SPMS, offers new therapeutic options and potentially improved treatment adherence. Neurologists
also discussed the potential of combination therapies that would reduce inflammation and simultaneously improve
myelin regeneration; however, such therapies are not anticipated in the near future.
The outcome of pipeline products for SPMS remains uncertain, predominantly due to the lack of treatment
sequencing and the prospects of overlapping drug labels. For novel SPMS drugs, the indications to include younger
as well as older patients remain an enigma owing to the lack of evidence. Positioning of potential DMTs for SPMS
would ideally be based on populations investigated in controlled settings. Clear communication of the value of
DMTs will be key for optimizing price and reimbursement. For emerging therapies in SPMS, a detailed analysis of
the clinical profile is essential to make a precise price assessment [30]. Moreover, studies on the possibility of using
RRMS drugs for SPMS have revealed unsatisfactory outcomes [31–34].
The reduced efficacy of RRMS biologics in SPMS is unlikely to have an impact on the price potential of therapies
specifically approved for SPMS, as drug prices are compared within the same indication. However, due to budget
constraints, the emerging oral therapies for SPMS are most likely to compete with interferons on drug price and
should be priced lower than ocrelizumab; for instance, to secure access at both national and regional levels across
the major countries in Europe.
Patient access to novel effective treatment options will facilitate and encourage the diagnosis of SPMS. Therefore,
it is fundamental for drug developers to explicitly communicate the added value of new drugs and make the
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information readily available to patients and stakeholders involved in SPMS patient care. Pharmaceutical companies
can substantiate treatment usefulness through RWE generation and obtain broad access for patients with SPMS.
The long-term cohort data would be helpful to validate the use of digital tools and aids [35].
Limitations
This is a qualitative research study. The participants responded to the questions and provided their feedback based
on their expertise. We included a panel of 58 local experts, randomly selected from seven European countries,
to get a balanced regional view; however, it would be beneficial to include the opinions of the stakeholders from
other countries as well. The perspectives of SPMS patients and caregivers were not included in this expert panel
discussion.
Conclusion
The perception of MS as ‘one disease’ has undergone a paradigm shift, with no clear differentiation between RRMS
and SPMS. Ambiguity also exists regarding the definition of SPMS and identification of active versus nonactive
forms of the disease. Although there are a number of challenges in clinical management (diagnosis and treatment)
of patients with SPMS, it is evident that the collaborative efforts of the associated stakeholders (neurologists, nurses,
caregivers, payers, patients and the pharmaceutical industry), along with advances in the understanding of SPMS
pathophysiology and diagnostic criteria, robust assessment guidelines, enhanced disease awareness and availability
of RWE in the future, will allow for optimal care that will improve the quality of life of people living with SPMS.
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